This entry covers evaluation under DC 7833. A clinician establishes the diagnosis separately.
How is it connected to service?
The applicable direct, secondary, aggravation or presumptive route determines the service-connection evidence. Use the evidence guide to distinguish these routes.
Explore service-connection evidence →What do the rating levels describe?
A diagnosis does not automatically establish a percentage. These are the source requirements for evaluating severity; related notes and exceptions still apply.
Find DC 7833 in the rating schedule
The highlighted row marks this code. Nearby rows provide context and can describe other conditions. Use the full schedule for applicable headings, footnotes and exceptions.
| Rating | |
|---|---|
| Unable to handle paper or tools because of moisture, and unresponsive to therapy | 30 |
| Able to handle paper or tools after therapy | 0 |
| 7833 Malignant melanoma: | |
| Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805), disfigurement of the head, face, or neck (DC 7800), or impairment of function (under the appropriate body system) | |
| Note: If a skin malignancy requires therapy that is comparable to that used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the skin, or surgery more extensive than wide local excision, a 100-percent evaluation will be assigned from the date of onset of treatment, and will continue, with a mandatory VA examination six months following the completion of such antineoplastic treatment, and any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e). If there has been no local recurrence or metastasis, evaluation will then be made on residuals. If treatment is confined to the skin, the provisions for a 100-percent evaluation do not apply. |
Related notes and evaluation rules
Note: If a skin malignancy requires therapy that is comparable to that used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the skin, or surgery more extensive than wide local excision, a 100-percent evaluation will be assigned from the date of onset of treatment, and will continue, with a mandatory VA examination six months following the completion of such antineoplastic treatment, and any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e). If there has been no local recurrence or metastasis, evaluation will then be made on residuals. If treatment is confined to the skin, the provisions for a 100-percent evaluation do not apply.
Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805), disfigurement of the head, face, or neck (DC 7800), or impairment of function (under the appropriate body system) |
Which evidence addresses the questions?
- Diagnosis and history: Records identifying the current diagnosis, onset, course, and relevant medical history.
- Treatment and medications: Treatment records, medication history, procedures, and therapy documentation.
- Symptoms and episodes: Records or statements documenting symptoms, severity, frequency, duration, and episodes.
- Clinical findings: Examination findings that are relevant to the public DBQ or rating criteria.
- Scars and residual findings: Records describing relevant scars and residual physical findings.
- Functional impact: Medical and lay evidence describing work and daily-activity effects.
- Service connection evidence: Evidence addressing an in-service event, exposure, disease, injury, continuity, or a secondary relationship.
Find evidence in the Skin Diseases questionnaire
Use these section names and page numbers to locate the examiner’s findings. Some sections apply only to particular diagnoses within this family.
- diagnosis · p. 2
- medical history · p. 3
- treatment · p. 3, 4, 5, 6
- physical exam · p. 6, 7
- specific skin conditions · p. 7, 8, 9
- tumors and neoplasms · p. 9, 10
- scarring and disfigurement · p. 10
- other pertinent physical findings, complications, conditions, signs and/or symptoms · p. 11
- functional impact · p. 11
- remarks · p. 12
Shared library and examination references
How an independent medical review works →Sources and scope
Clinical and evidence sources
Guide source check: 2026-11-06. Rating-library snapshot: June 30, 2026. Source coverage is distinct from clinical review. This page does not diagnose, adjudicate a claim, or collect medical records.
Shared reference edition 1.2.4 · source check 2026-11-06. Coverage is stated for each framework and is distinct from clinical review. Rating-source snapshot: 2026-06-30.